Dottikon ES Holding AG Logo

Dottikon ES Holding AG

Manufactures chemicals and APIs, specializing in hazardous reactions.

DESN | SW

Overview

Corporate Details

ISIN(s):
CH0582581713
LEI:
50670064H782SV8G2Z44
Country:
Switzerland
Address:
Hembrunnstrasse 17, 5605 Dottikon

Description

Dottikon ES Holding AG manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for the chemical, biotech, and pharmaceutical industries. The company specializes in hazardous reactions, positioning itself as a strategic development and manufacturing partner. Its services encompass research and development, route finding, process development, and process intensification. Dottikon operates multi-ton production facilities under cGMP standards, with approvals from regulatory bodies including the FDA and Swissmedic, managing the entire product lifecycle from development to large-scale manufacturing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dottikon ES Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dottikon ES Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Dottikon ES Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-06-18 N/A Executive member Sell None 19,500,000.00 CHF
2023-07-24 N/A Executive member Sell None 72,600.00 CHF
2023-06-15 N/A Executive member Sell None 85,872,280.00 CHF
2023-06-15 N/A Non-Executive member Buy None 26,000.00 CHF
2023-06-01 N/A Non-Executive member Buy None 30,240.00 CHF

Peer Companies

ALNYLAM PHARMACEUTICALS, INC. Logo
A biopharmaceutical company developing RNA interference (RNAi) therapeutics.
United States of America
ALNY
Alpha Cognition Inc. Logo
A biopharmaceutical company developing treatments for neurodegenerative diseases.
United States of America
ACOG
Alpha Teknova, Inc. Logo
Manufacturer of critical reagents for the life sciences industry.
United States of America
TKNO
ALTERITY THERAPEUTICS LTD Logo
A clinical-stage biotech developing novel treatments for neurodegenerative diseases.
United States of America
ATHE
Altimmune, Inc. Logo
Clinical-stage biopharma developing peptide therapeutics for obesity and liver diseases.
United States of America
ALT
Alto Neuroscience, Inc. Logo
Develops precision medicines for neuropsychiatric conditions using patient biology.
United States of America
ANRO
ALUMIS INC. Logo
Clinical-stage biopharma developing precision medicines for autoimmune diseases.
United States of America
ALMS
Alvotech Holdings S.A Logo
A biotechnology company developing and manufacturing biosimilar medicines worldwide.
Luxembourg
ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage immuno-oncology company developing therapies to combat cancer.
United States of America
ALXO
Alzamend Neuro, Inc. Logo
Develops treatments for neurodegenerative diseases and psychiatric disorders.
United States of America
ALZN

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.